How to Pivot Neurodegeneration Treatment Research?

As the furthest developed new Alzheimer’s therapy candidate approaches a regulatory review decision, in a field historically focused on beta-amyloid plaques as primary targets, what aligned and alternative approaches to neurodegenerative treatment are showing greatest progress?  This panel brings together investors, clinical development experts, and companies expanding the toolbox of neurodegeneration therapies.  Collectively, panelists will discuss the most promising mechanisms of action, but how pivoting investment in brain health R&D is producing positive results for diagnostic biomarkers as well therapeutics in multiple neurodegeneration-related indications.